Evandro José Cesarino

Prof. Dr. Evandro José Cesarino

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
WBWeimar Kunz Sebba Barroso
Weimar Kunz Sebba Barroso
CRCibele Isaac Saad Rodrigues
Cibele Isaac Saad Rodrigues
LBLuiz Bortolotto
Luiz Bortolotto
MMMarco Antônio Mota-Gomes
Marco Antônio Mota-Gomes
ABAndréa Araujo Brandão
Andréa Araujo Brandão
WNWilson Nadruz
Wilson Nadruz
Sumário 1. Definição, Epidemiologia e Prevenção Primária 528 1.1 Definição de Hipertensão Arterial 528 […] Diretrizes Brasileiras de Hipertensão Arterial – 2020 Sumário 1. Definição, Epidemiologia e Prevenção Primária 528 1.1 Definição de Hipertensão Arterial 528 […] Diretrizes Brasileiras de Hipertensão Arterial – 2020

5 March 2011 in Trials
Verified
Journal Article
Open access
PDF file
FFFlávio Danni Fuchs
Flávio Danni Fuchs
SFSandra Fuchs
Sandra Fuchs
LMLeila Beltrami Moreira
Leila Beltrami Moreira
MGMiguel Gus
Miguel Gus
ANAntônio C Nóbrega
Antônio C Nóbrega
OBOtávio Berwanger
Otávio Berwanger
Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage. This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil. Clinical Trials NCT00970931 .

1 October 1996 in Journal of Chromatography B: Biomedical Sciences and Applications
Verified
Journal Article
Closed access
VLVera Lucia Lanchote
Vera Lucia Lanchote
PBPierina Sueli Bonato
Pierina Sueli Bonato
SDSônia A.C. Dreossi
Sônia A.C. Dreossi
PGPaulo V.B. Gonçalves
Paulo V.B. Gonçalves
ECEvandro José Cesarino
Evandro José Cesarino
CBCarlo Bertucci
Carlo Bertucci

1 January 2003 in Chirality
Verified
Journal Article
Closed access
PDF file
PCPaula Macedo Cerqueira
Paula Macedo Cerqueira
ECEvandro José Cesarino
Evandro José Cesarino
CBCarlo Bertucci
Carlo Bertucci
PBPierina Sueli Bonato
Pierina Sueli Bonato
VLVera Lucia Lanchote
Vera Lucia Lanchote

1 August 2008 in Revista Latino-Americana de Enfermagem
Verified
Journal Article
Open access
PDF file
MSManuel Simão
Manuel Simão
MHMiyeko Hayashida
Miyeko Hayashida
CSCláudia Benedita dos Santos
Cláudia Benedita dos Santos
ECEvandro José Cesarino
Evandro José Cesarino
MNMaria Suely Nogueira
Maria Suely Nogueira
This descriptive study aimed to investigate the prevalence of hypertension and its risk factors among undergraduate students in Lubango-Angola. The results obtained according to the health field model were: a) human biology: 61.3% were between 18 and 29 years old; prevalence of hypertension from 20.3 to 26.7%; 17.1% were overweight; 3.2% were obese; b) environment: 36.1% were exclusively students; 33.1% gained a family income of up to 250 dollars; c) life style: 86.2% practiced physical activity; 60.6% preferred salty food; 4.0% were smokers; 40.6% drank alcohol; d) health care: 82.8% already had their arterial pressure verified sometime in their life, and 65.4% did not remember the obtained value.

1 March 2012 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
ECEvandro José Cesarino
Evandro José Cesarino
AVAndré Luiz Gomes Vituzzo
André Luiz Gomes Vituzzo
JSJulliane Messias Cordeiro Sampaio
Julliane Messias Cordeiro Sampaio
DFDanilo Avelar Sampaio Ferreira
Danilo Avelar Sampaio Ferreira
HPHeloísa Andrião Ferreira Pires
Heloísa Andrião Ferreira Pires
LSLuiz de Souza
Luiz de Souza
OBJECTIVE: To assess the cardiovascular risk, using the Framingham risk score, in a sample of hypertensive individuals coming from a public primary care unit. METHODS: The caseload comprised hypertensive individuals according to criteria established by the JNC VII, 2003, of 2003, among 1601 patients followed up in 1999, at the Cardiology and Arterial Hypertension Outpatients Clinic of the Teaching Primary Care Unit, at the Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. The patients were selected by draw, aged over 20 years, both genders, excluding pregnant women. It was a descriptive, cross-sectional, observational study. The Framingham risk score was used to stratify cardiovascular risk of developing coronary artery disease (death or non-fatal acute myocardial infarction). RESULTS: Age range of 27-79 years ( = 63.2 ± 9.58). Out of 382 individuals studied, 270 (70.7%) were female and 139 (36.4%) were characterized as high cardiovascular risk for presenting diabetes mellitus, atherosclerosis documented by event or procedure. Out of 243 stratified patients, 127 (52.3%) had HDL-C < 50 mg/dL; 210 (86.4%) had systolic blood pressure > 120 mmHg; 46 (18.9%) were smokers; 33 (13.6%) had a high cardiovascular risk. Those added to 139 enrolled directly as high cardiovascular risk, totaled up 172 (45%); 77 (20.2%) of medium cardiovascular risk and 133 (34.8%) of low risk. The highest percentage of high cardiovascular risk individuals was aged over 70 years; those of medium risk were aged over 60 years; and the low risk patients were aged 50 to 69 years. CONCLUSION: The significant number of high and medium cardiovascular risk individuals indicates the need to closely follow them up.